For example, the WT1-targeted DC vaccine combined with chemotherapy significantly activated WT1-specific immune responses, facilitated conversion surgery in patients with unresectable pancreatic ductal adenocarcinoma (UR-PDAC), and notably improved long-term clinical outcomes [405].Additionally, DCs transfected with MUC1 mRNA achieved a one-year survival rate of over 50% in advanced PC patients [406]. The gene discussed is WT1; the disease is pancreatic ductal adenocarcinoma.